Pre-filled Syringe Presentation of BYOOVIZ®, Samsung Bioepis' Biosimilar to Lucentis (Ranibizumab), Gains European Approval
Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for BYOOVIZ® pre-filled syringe (PFS), a biosimilar referencing Lucentis1 (ranibizumab). BYOOVIZ was first approved by the European Commission (EC) in August 2021 as a single use vial for intravitreal use (0.5 mg/0.05 ml) for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to diabetic macular oedema (DME), proliferative diabetic retinopathy (PDR), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) and visual impairment due to choroidal neovascularization (CNV).
The PFS presentation is regarded as the standard of care in ophthalmology, providing convenience for administration with precise dosing and ease of use with syringe injection, as well as safety benefits in the form of a decreased risk of endophthalmitis versus vials.2
“As Samsung Bioepis starts to commercialize BYOOVIZ in January 2026, the addition of this PFS presentation will provide additional value for our stakeholders, by helping providers manage ophthalmic conditions with convenience for injection,” said Antonio Rito, Vice President and Head of Europe at Samsung Bioepis. “We will continue to provide biosimilar medicines with improved product features to meet the needs of healthcare providers and patients.”
In October 2025, Samsung Bioepis announced that the company will assume full commercial responsibility for BYOOVIZ in Europe upon full transition of Biogen’s commercialization rights back to Samsung Bioepis effective as of January 2026. The PFS presentation is expected to be available in the market starting in the second quarter of 2026.
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit www.samsungbioepis.com and follow us on social media – LinkedIn, X.
1 Lucentis is a trademark of Genentech Inc.
2 Uzzan J, Mapani A, Cox O, Bagijn M, Saffar I. Clinical Outcomes and Experiences with Prefilled Syringes Versus Vials for Intravitreal Administration of Anti-VEGF Treatments: A Systematic Review. Ophthalmol Ther. 2024 Sep;13(9):2445-2465. doi: 10.1007/s40123-024-01002-0. Epub 2024 Jul 27. PMID: 39066961; PMCID: PMC11341511.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251201515215/en/
Contacts
MEDIA CONTACT
Anna Nayun Kim, nayun86.kim@samsung.com
Yoon Kim, yoon1.kim@samsung.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Payments Modernisation: Gap Between Confidence and Readiness Among Industry Leaders Widens, ACI Worldwide Study Finds2.12.2025 09:00:00 EET | Press release
Payments leaders remain confident about the pace of industry innovation, but many risk falling behind as expectations accelerate. New global research from ACI Worldwide (NASDAQ: ACIW) and Globant reveals a widening gap between confidence and readiness that could define industry leadership in 2026 and beyond. The report Payments in Transition: Leadership in an era of transformation, based on a survey of 500 industry leaders across North America, Europe, Latin America, Middle East & Africa, and Asia Pacific, shows that while 69% of executives consider their organisations to be payments leaders, fewer than half (44%) say payments innovation is a C-suite priority. This disconnect is driven by barriers that will become increasingly costly in the year ahead. More than half (55%) of executives admit they are not fully using the technology already available, and 44% cite legacy platforms as the biggest obstacle to innovation. Internal resistance compounds the challenge, with 53% pointing to cu
Oulu Launches Its European Capital of Culture Year with a Three-day Opening Festival2.12.2025 08:00:00 EET | Press release
The Oulu2026 Opening Festival on 16–18 January 2026 transforms the city centre into a vibrant celebration of culture, community and northern creativity. It marks the beginning of a historic year and invites residents, visitors and partners from Finland, Europe and beyond to take part in a unique moment for Oulu and its 39 partner municipalities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201071170/en/ In January, Oulu’s city centre will transform into the Oulu2026 Opening Festival area. Photo: Harri Tarvainen / City of Oulu image bank. “After years of preparation, Oulu2026 is finally here. The Opening Festival gives everyone a chance to be part of something that will only happen once, and it all begins in the heart of Oulu,” says Piia Rantala-Korhonen, CEO of Oulu2026. Almost 200 events, over 20 venues The Opening Festival presents a wide range of art and cultural experiences all over the city centre. From exhibitions
Murata Unveils World’s First 15nF/1.25kV C0G MLCC in 1210-inch Size2.12.2025 04:00:00 EET | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) announces the launch and mass production of its multilayer ceramic capacitor (MLCC) featuring a capacitance of 15nF, a rated voltage of 1.25kV, and C0G characteristics in the compact 1210-inch (3.2mm x 2.5mm) size. This product delivers highly efficient power conversion and stable performance under high-voltage conditions, making it suitable for onboard chargers (OBCs) in electric vehicles (EVs) and power supply circuits in high-performance consumer devices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201104421/en/ [Murata Manufacturing Co., Ltd.] 15nF/1.25kV/C0G MLCC in 1210-inch Size Resonant and snubber circuits are essential for efficient power conversion and suppressing current and voltage peaks. In both circuits, repeated exposure to high voltage and high current can cause even slight changes in component performance, leading to efficiency loss or
With 40% of Agentic AI Projects Predicted to Fail, Leading Software Developer Says Compliance Is the One Place Where Agentic AI Will Thrive2.12.2025 02:01:00 EET | Press release
The CEO of one of the world’s leading global compliance software developers, Ideagen, has today (December 2, 2025) said compliance represents the one domain where autonomous AI will succeed – despite technology insights company Gartner® warning "… over 40% of agentic AI projects will be canceled by the end of 2027”. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201511477/en/ Ben Dorks, Ideagen CEO Speaking at the launch of their own agentic AI platform Ideagen Mazlan, Ben Dorks said: “Autonomous AI will succeed in compliance because failure is measurable, stakes are high and outcomes are binary. “AI that continuously monitors jurisdictional or industry specific compliance frameworks, detects patterns across thousands of records, raises actions for others to follow, flags gaps before audits, autonomously? That's agentic. It will literally save lives and is the most transformative shift in protecting people, products and p
VeriSilicon’s NPU IP VIP9000NanoOi-FS has Achieved ISO 26262 ASIL B Certification2.12.2025 02:00:00 EET | Press release
VeriSilicon (688521.SH) today announced that its NPU IP VIP9000NanoOi-FS has successfully achieved ISO 26262 ASIL B certification, marking a significant milestone in the functional safety capabilities of the company’s neural network processing unit portfolio. This IP features an architecture streamlined for seamless SoC integration, delivering high-quality inference with low power consumption and a compact silicon footprint. The certificate was issued by SGS-TÜV Saar, an international testing, inspection and certification institution. As part of VeriSilicon’s VIP9000 series, the VIP9000NanoOi-FS IP is designed for automotive and edge AI applications, providing high-performance neural network processing with a safety-compliant architecture. The IP supports a wide range of AI inferencing models including Large Language Models (LLMs) and Convolutional Neural Networks (CNNs), with hardware-accelerated AI inference, enabling real-time applications such as object and scene detection, augment
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom